84 related articles for article (PubMed ID: 3319280)
1. Study of the immune complex precipitation-inhibiting capacity of sera of patients with chronic lymphocytic leukaemia.
Varga L; Miszlay Z; Czink E; Pálóczi K; Szegedi G; Füst G; Hollán SR
Diagn Clin Immunol; 1987; 5(3):129-34. PubMed ID: 3319280
[TBL] [Abstract][Full Text] [Related]
2. Depressed classical complement pathway activities in chronic lymphocytic leukaemia.
Füst G; Czink E; Minh D; Miszlay Z; Varga L; Hollán SR
Clin Exp Immunol; 1985 Jun; 60(3):489-95. PubMed ID: 4017286
[TBL] [Abstract][Full Text] [Related]
3. Difference in the biological properties of the two forms of the fourth component of human complement (C4).
Schifferli JA; Steiger G; Paccaud JP; Sjöholm AG; Hauptmann G
Clin Exp Immunol; 1986 Feb; 63(2):473-7. PubMed ID: 3486068
[TBL] [Abstract][Full Text] [Related]
4. Presence of circulating immune complexes in patients with chronic lymphocytic leukaemia. Correlations between clinical and immunological features.
Mozzana R; Baldini L; Neri A; Cortelezzi A; Radaelli F; Colajori E; Polli EE
Boll Ist Sieroter Milan; 1982; 61(4):324-9. PubMed ID: 6927220
[TBL] [Abstract][Full Text] [Related]
5. Complement-mediated inhibition of immune precipitation in patients with immune complex diseases.
Naama JK; Mitchell WS; Zoma A; Veitch J; Whaley K
Clin Exp Immunol; 1983 Feb; 51(2):292-8. PubMed ID: 6220848
[TBL] [Abstract][Full Text] [Related]
6. Circulating immune complexes associated with decreased complement-mediated inhibition of immune precipitation in sera from patients with bacterial endocarditis.
Kerr MA; Wilton E; Naama JK; Whaley K
Clin Exp Immunol; 1986 Feb; 63(2):359-66. PubMed ID: 3698338
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of immune precipitation by complement.
Hong K; Takata Y; Sayama K; Kozono H; Takeda J; Nakano Y; Kinoshita T; Inoue K
J Immunol; 1984 Sep; 133(3):1464-70. PubMed ID: 6747294
[TBL] [Abstract][Full Text] [Related]
8. C1 and C4 abnormalities in chronic lymphocytic leukaemia and their significance.
Füst G; Miszlay Z; Czink E; Varga L; Pálóczi K; Szegedi G; Hollán SR
Immunol Lett; 1987 Feb; 14(3):255-9. PubMed ID: 3570363
[TBL] [Abstract][Full Text] [Related]
9. Complement-mediated immune complex solubilization and precipitation inhibition in sera of patients with non-Hodgkin's lymphoma.
Bányai A; Pálóczi K; Csipö I; Csongor J; Szegedi G
Haematologia (Budap); 1990; 23(2):87-95. PubMed ID: 2272539
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of complement components in polyethylene glycol precipitated immune complexes from patients with ovarian cancer and patients with rheumatoid arthritis.
Mooney NA; Hay FC; Poulton TA
Clin Exp Immunol; 1983 Jun; 52(3):561-8. PubMed ID: 6603297
[TBL] [Abstract][Full Text] [Related]
11. Serial measurement of circulating immune complexes in the sera of patients with leukaemia.
Mód A; Carpentier N; Füst G; Lambert PH; Miescher P; Hollán SR
J Clin Lab Immunol; 1980 Jul; 4(1):15-20. PubMed ID: 7007648
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of complement-mediated solubilization of antigen-antibody complexes by sera from patients with rheumatoid arthritis.
Naama JK; Mitchell WS; Whaley K
Clin Exp Immunol; 1983 Nov; 54(2):429-38. PubMed ID: 6652966
[TBL] [Abstract][Full Text] [Related]
13. The role of C1, C1-inactivator and C4 in modulating immune precipitation.
Schifferli JA; Steiger G; Schapira M
Clin Exp Immunol; 1985 Jun; 60(3):605-12. PubMed ID: 4017288
[TBL] [Abstract][Full Text] [Related]
14. Evidence for immune complexes involving anti-lymphocyte antibodies associated with hypocomplementaemia in chronic lymphocytic leukaemia (CLL).
Day NK; Winfield JB; Gee T; Winchester R; Teshima H; Kunkel HG
Clin Exp Immunol; 1976 Nov; 26(2):189-95. PubMed ID: 136325
[TBL] [Abstract][Full Text] [Related]
15. Repressed classical complement pathway activities and clinical correlations in chronic lymphocytic leukaemia.
Miszlai Z; Czink E; Varga L; Pálóczi K; Szegedi G; Füst G; Hollán SR
Acta Med Hung; 1986; 43(4):389-95. PubMed ID: 3601584
[TBL] [Abstract][Full Text] [Related]
16. Solubilization of immune complexes and inhibition of immune precipitation in SLE sera.
Balestrieri G; Pagani D; Tincani A
J Clin Lab Immunol; 1983 Nov; 12(3):147-50. PubMed ID: 6663608
[TBL] [Abstract][Full Text] [Related]
17. Complement activation and impaired capacity to solubilize immune complexes or to prevent their formation in essential mixed cryoglobulinemia.
Corvetta A; Spaeth PJ; Ghirelli PA; Orecchioni F; Buetler R; Montroni M; Nydegger UE
Diagn Immunol; 1983; 1(4):315-23. PubMed ID: 6333960
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent redistribution and release of immunological complexes in cells of human chronic leukemias.
Harłozińska A; Noworolska A; Richter R; Becker M
Folia Haematol Int Mag Klin Morphol Blutforsch; 1980; 107(1):27-35. PubMed ID: 6157621
[TBL] [Abstract][Full Text] [Related]
19. Influence of immune-complex size and antigen-antibody ratio on immune complex detection with monoclonal rheumatoid factor and C1q.
Vanham G; Bloemmen FJ; Ceuppens JL; Stevens EA
J Clin Lab Immunol; 1984 Oct; 15(2):63-8. PubMed ID: 6335179
[TBL] [Abstract][Full Text] [Related]
20. C4A deficiency and elevated level of immune complexes: the mechanism behind increased susceptibility to systemic lupus erythematosus.
Traustadottir KH; Sigfusson A; Steinsson K; Erlendsson K
J Rheumatol; 2002 Nov; 29(11):2359-66. PubMed ID: 12415592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
